Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Financial Statements
- Click here to download Alexion Pharmaceuticals Inc.'s Income Statement
- Click here to download Alexion Pharmaceuticals Inc.'s Balance Sheet
- Click here to download Alexion Pharmaceuticals Inc.'s Statement of Cash Flows
Key Info
- Industry: Pharmaceutical Preparation Manufacturing
- Sector: Manufacturing
- CEO Name: Ludwig Hantson
Key Statistics
- Stock Price: $182.5
- Dividend Yield: 0%
- Market Capitalization: $0
- Shares Outstanding: 221,019,230
- Number of Employees: 2,525
- Trailing 12-Month EPS: $3.07
- Trailing 12-Month DPS: $0
- Payout Ratio: 0.0%
Important Dates
- Next Earnings Date:
- Next Ex-Dividend Date:
Price Trends
- Current Stock Price: $182.5
- 52-week high: $0
- 52-week low: $0
- 200-day moving average: $0
- 50-day moving average: $0
Performance
- 1-Month Price Return: 0%
- 3-Month Price Return: 0%
- 6-Month Price Return: 0%
- 1-Year Price Return: 0%
- 2-Year Price Return: 0%
- 5-Year Price Return: 0%
Visit the Passiv Stock Directory
Data provided by IEX Cloud
For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast